Program
acoramidis
Also written as “Acoramidis”, “Acoramidis (AG10)” and “AG10”.
Its studies are mostly in Amyloid Neuropathies, Familial · Amyloidosis, Hereditary, Transthyretin-Related · Amyloidosis, led by 3 companies.
Drug pageAcoramidis: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBioits history only | 114 open or running | phase 4since Jul 6, 2026 | Sep 18, 2017 | Apr 15, 2028phase 3 · NCT04988386 |
| AstraZeneca | 31 open or running | phase 4since Dec 15, 2025 | Nov 6, 2020 | Mar 31, 2028phase 4 · NCT07306949 |
| Bayerits history only | 11 open or running | phase 4since Dec 11, 2025 | Dec 11, 2025 | Sep 17, 2027phase 4 · NCT07298044 |
Also a collaborator on its studies: Celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2019Named acoramidisINNProposed as its International Nonproprietary Name in WHO's List 122
- Nov 6, 2020First study: phase 3 study in Symptomatic Transthyretin Amyloid CardiomyopathyFirst studyNCT04622046 · 25 enrolled · Japan
- Jul 1, 2021Phase 1 study in HealthyNCT04958135 · 18 enrolled · United States
- Dec 15, 2025Phase 4 study in Transthyretin-type Cardiac AmyloidosisNCT07306949 · 200 planned · Japan
Ahead
- Mar 31, 2028Primary completion: phase 4 study in Transthyretin-type Cardiac AmyloidosisNCT07306949
TargetBeta
“Transthyretin stabiliser; Transthyretin stabiliser”ChEMBL 37, by rule
Other programs on TTR
Studies
All 3 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07306949Transthyretin-type Cardiac Amyloidosis · Japan | 4 | Recruiting | Mar 31, 2028 | 200 |
| NCT04958135Healthy · United States | 1 | Completed | Aug 4, 2021 | 18 |
| NCT04622046Symptomatic Transthyretin Amyloid Cardiomyopathy · Japan | 3 | Completed | Nov 8, 2023 | 25 |
How it is read
Names in the registry
- “Acoramidis”, 6 entries
- “Acoramidis (AG10)”, 2 entries
- “AG10”, 2 entries
- “acoramidis”, 2 entries
- “Acoramidis (AG10) oral tablet”, 1 entry
Conditions, from the studies’ own filings
- Amyloid Neuropathies, Familial, 5 studies
- Amyloidosis, Hereditary, Transthyretin-Related, 4 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.